ABSTRACT
INTRODUCTION
Tuberculosis remains a key cause of death among people with HIV 1 in sub-Saharan
Africa despite wider use of antiretroviral therapy (ART). [2] [3] [4] Diagnosis is complicated by the high proportion who are smear-negative, 5, 6 and atypical chest radiograph findings. 7 Intensified tuberculosis case finding (ICF) is recommended by the World Health
Organization (WHO) 8 but is poorly implemented. 9 Screening prior to ART is particularly important because risk of tuberculosis and death is high for immunosuppressed individuals. 4, 10 Individuals diagnosed with tuberculosis after, rather than before, ART initiation are more likely to die while on tuberculosis treatment, emphasising the need for prompt diagnosis and treatment initiation. 3 High tuberculosis incidence within the first few months of ART initiation suggests that cases are either missed at screening or subclinical disease is unmasked by immunological recovery. [10] [11] [12] The aim of our study was to determine the prevalence of previously undiagnosed active tuberculosis amongst ART-eligible adults at enrolment to a public sector HIV clinic in South Africa, and to evaluate the performance of combinations of symptoms and standard investigations in the diagnosis of tuberculosis.
METHODS

Study design and population
Between Patients were referred to this clinic for ART initiation. South African guidelines 13 at the time of this study did not specify systematic screening for tuberculosis prior to ART. Clinic policy was for routine chest radiography at enrolment, but systematic tuberculosis screening was not routine; patients were assessed by clinicians for ART eligibility and investigated as deemed appropriate. All patients with CD4<200 
Study procedures
Trained nurses administered a symptom questionnaire and collected two spot sputum specimens for smear and mycobacterial culture from all participants. Chest radiographs were read by a consultant physician blinded to clinical details, using a standardised form adapted from a validated tool, 14 assigning radiographic diagnoses according to overall impression. We reviewed patients 3-6 months post enrolment, performing repeat symptom questionnaire and record review, and investigated symptomatic patients with chest radiography and two further sputum specimens.
Symptomatic patients were those with any of: cough, night sweats, fever, appetite loss, tiredness for >2 weeks; or haemoptysis, chest pain, difficulty breathing, observed weight loss >1.5kg in previous month; or self-reported weight loss over the preceding 6 months. Patient records were used to ascertain CD4 and full blood counts, WHO clinical stage, tuberculosis diagnoses made outside of study visits, and evidence of clinical improvement at two months amongst those on tuberculosis treatment. Tuberculosis diagnosed at recruitment was not used to assign WHO stage.
Laboratory methods
Sputum specimens were examined at the National Health Laboratory Services by fluorochrome staining for acid-fast bacilli (AFB), and cultured using the BACTEC TM MGIT 960 TM system (Becton Dickinson Microbiology Systems, Sparks, MD, USA).
Scanty positive smears were considered positive. All positive cultures were identified using a nucleic amplification technique (AccuProbe®, Gen-Probe, San Diego, CA, USA).
Case definition for tuberculosis
Patients were classified as having pulmonary tuberculosis (PTB) if they had compatible clinical or radiological features and: sputum culture-positive for M.
tuberculosis (definite PTB); sputum smear-positive, culture-negative (probable PTB);
or no other cause of disease found and clinical improvement after two months of tuberculosis treatment, or lost to follow-up or died before two months (possible PTB).
Patients were classified as having extrapulmonary tuberculosis (EPTB) if they had compatible clinical features and either had: M. tuberculosis cultured from a relevant site (definite EPTB); other diagnostic evidence of EPTB and improved after two months of tuberculosis treatment (probable EPTB); or no other cause of disease was found and the patient improved after two months of tuberculosis treatment or was lost to follow-up or died before two months (possible EPTB). Tuberculosis episodes were considered to start on the date tuberculosis treatment was started.
Prevalent tuberculosis was defined as any tuberculosis episode fulfilling case definitions within three months of enrolment. Only study screening tests performed on the day of enrolment were used to calculate sensitivity, specificity, negative and positive predictive values for screening methods. Information from all available sources was used to assign tuberculosis case definitions.
Statistical analysis
Data were analysed using Intercooled Stata 10.0 (Stata Corporation, Texas, USA).
We used logistic regression to calculate unadjusted and adjusted odds ratios for risk factors for prevalent tuberculosis and to assess the performance of symptoms for a screening tool using a gold standard of culture-positive tuberculosis. 
RESULTS
Participation and demographics
Sputum microscopy and culture results
Amongst 350 individuals with sputum results available, 24 (7%) and 326 (90%) produced one or two adequate sputum specimens respectively. 9/350 (3%) were smear-positive and 64/350 (18%) were culture-positive for M. tuberculosis, of whom one was culture-negative at enrolment but culture-positive subsequently. 7/350 (2%)
were both smear-and culture-positive. Amongst 300 patients with a negative or inadequate first sputum specimen, 14 (5%) had a culture-positive second specimen.
57/64 (89%) of culture-positive patients were smear-negative.
Time from screening to start of treatment
Amongst 86 patients with definite, probable or possible tuberculosis, and for whom the basis of starting treatment was clear, the median time to starting treatment was 
Demographic and clinical risk factors for undiagnosed prevalent tuberculosis
Risk factor analyses were restricted to 300 individuals (6 "probable" and 44 "possible" tuberculosis cases, and 11 individuals without sputum results were excluded). In the univariable analysis (see supplementary appendix table 2), prevalent tuberculosis was associated with male sex, greater than six household members, ever having smoked, and no previous history of tuberculosis treatment. In the multivariable analysis only previous tuberculosis treatment, which was protective, (adjusted OR 0.29, 95% CI 0.13-0.65) remained associated.
Sensitivity, specificity and predictive values of markers for undiagnosed prevalent tuberculosis
Using culture-positive tuberculosis as our gold standard we found that the presence of individual symptoms irrespective of duration was sensitive, but generally had low specificity, except for haemoptysis which had low prevalence ( , and any abnormality on chest radiograph (table 1) . In terms of specificity and positive predictive value the best symptom, sign and investigation were fever >2
weeks, observed fever (although only two participants were febrile), and sputum microscopy respectively.
Combinations of screening criteria
The three symptoms with the highest adjusted odds ratios in multivariable analysis were cough>2 weeks, loss of appetite >2 weeks and night sweats >2 weeks (for details, see supplementary appendix and BMI <18.5 further increased sensitivity to 90% but halved specificity.
Sputum microscopy did not change the performance of the symptom complex, in contrast to chest radiography which increased sensitivity to 92% for features compatible with active tuberculosis, and 96% for any radiographic abnormality. A combination of symptom complex or any radiographic abnormality had sensitivity and negative predictive values of 96%, which was further improved by addition of CD4<100 which missed only 2% of tuberculosis cases and was our most sensitive combination (98%).
The WHO symptom screen 17 had sensitivity, specificity, positive and negative predictive values of 96%, 5%, 21% and 83% respectively in our patients. Addition of chest radiography increased sensitivity and negative predictive value to 100% for both features compatible with active tuberculosis and any radiographic abnormality. 
Time to ART start and mortality
DISCUSSION
One-third of our patients referred to start ART had undiagnosed tuberculosis, a major burden of morbidity with life-threatening potential; 10, 11 highlighting the need to investigate all of these patients, most of whom were highly symptomatic, for tuberculosis. Our prevalence is similar to recent data from Western Cape (32%), 12 but higher than generally reported among ART-eligible adults in Africa (3%-19%). 10, 11, 16, [18] [19] [20] This reflects systematic screening of our patients using multiple modalities, and a broad case definition allowing diagnosis based on radiological and clinical features highlighting the 'real life' burden, and recognising that sputum culture misses some cases of disseminated tuberculosis. 21 Our 18% prevalence of cultureconfirmed pulmonary tuberculosis accords with studies from Cambodia (17%), 22 KwaZulu-Natal (19%), 16 and Western Cape (17%). 15 We found demographic and clinical data unhelpful in identifying subgroups at higher risk of undiagnosed tuberculosis. Individuals with advanced HIV disease often reach HIV care due to symptoms of tuberculosis, underscoring the need for systematic case finding. Screening for this group requires high sensitivity to avoid missing cases, but in a resource-constrained setting, this must be balanced against the high costs resulting from a test combination with poor specificity. We found sputum microscopy had very poor sensitivity, consistent with other studies, 16, 19, [23] [24] [25] as Xpert MTB/RIF 27 at US$17 per cartridge, 28 the cost to health services may be substantial, and the cost-effectiveness of a range of algorithms for different settings needs to be investigated. 90% of our culture-proven tuberculosis cases were smearnegative, and Xpert MTB/RIF has reported sensitivities from 43%-73% for smearnegative culture-positive tuberculosis from a single sputum sample. 15, 27 An algorithm requiring Xpert-negative tuberculosis suspects to undergo further evaluation using sputum culture, trial of antibiotic and chest radiograph has potential to delay tuberculosis treatment.
Chest radiography improved sensitivity of our symptom screening complex substantially, consistent with our earlier data from South African gold miners with less advanced HIV disease. 23 Use of chest radiography to augment the WHO symptom screen in high tuberculosis prevalence settings is supported by a recent meta-analysis 26 and WHO guidance, 17 and in our study population increased sensitivity and negative predictive value to 100%. Our data show that chest radiography facilitates prompt tuberculosis treatment initiation. Although implementation of chest radiography can be challenging, 29, 30 we suggest it should be done where possible. In high prevalence settings systematic sputum culture for all patients prior to ART has also been suggested, but presents the same challenges of access. 12, 16 In our study, most culture-positive patients started tuberculosis treatment based on clinical and radiological features prior to availability of culture results; even with liquid culture, the median time to tuberculosis treatment start based on a positive culture was 37 days.
Chest radiography provides a basis for rapid initiation of tuberculosis treatment both to reduce individual risk of death and also reduce risk of onward transmission in both clinic and community, and procedures must be in place to ensure follow-up of tuberculosis suspects. 30 The cost per chest radiograph has been estimated at only US$2. 30 The reported sensitivity of Xpert MTB/RIF among smear-negative tuberculosis cases (most ART-eligible patients will be smear-negative) is lower than chest radiography in this study, but it has much higher specificity. 27 Implementation of Xpert MTB/RIF should similarly reduce time to tuberculosis treatment start, but cost is likely to limit its wide use at peripheral health facilities, and effective low-cost point-ofcare diagnostic tools remain a pressing need.
A low haemoglobin level is an independent predictor for mortality amongst patients commencing antiretroviral therapy [31] [32] [33] and may reflect undiagnosed tuberculosis.
Adding anaemia to our symptom complex increased sensitivity, and supports the clinical practice of investigating all anaemic patients for tuberculosis prior to initiation of ART.
A major strength of our study was our longitudinal follow-up period, which is lacking from many screening studies, 19 minimising the number of tuberculosis cases missed and ensuring a robust case definition for possible tuberculosis. One-third of participants without a review visit are known to have died, underscoring how ill individuals were at enrolment. Tuberculosis cannot be excluded as cause of death amongst all; hence we may have underestimated the true tuberculosis prevalence.
The study setting in a large public sector clinic is relatively typical of antiretroviral roll out sites, although better resourced than many in sub-Saharan Africa. We had access to routine radiographs, read by an experienced physician, and mycobacterial cultures, and good patient retention in the study. Our screening procedure was straightforward to operationalise and did not appear to delay initiation of ART; the typical time from first visit to ART initiation in this clinic was 60-90 days (personal communication, E Variaiva).
In conclusion we found a very high prevalence of undiagnosed tuberculosis among patients presenting for ART to a public sector HIV clinic. These patients need routine systematic investigation for tuberculosis. Until accurate point-of-care diagnostic tests are available, our results suggest that chest radiography is a useful addition to routine screening which allows rapid initiation of tuberculosis treatment. Given the high mortality of patients awaiting investigation results, 2,4,34 presumptive tuberculosis treatment for high-risk individuals also needs to be evaluated. 
